Cargando…
非小细胞肺癌分子靶向治疗中EGFR-TKI的耐药机制研究进展
With a greater understanding of tumor biology, novel molecular-targeted strategies that block cancer progression pathways have been evaluated as a new therapeutic approach for treating non-small cell lung cancer (NSCLC). Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), such a...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000259/ https://www.ncbi.nlm.nih.gov/pubmed/22336239 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.08 |